Inclusion Criteria:

- Cases with Stage I-IIIA Breast Cancer treated with anthracyclines and taxanes (within
90 days)

- Able to understand and sign the informed consent

- Intact vision (visual acuity 20/40)

- Native English-speaking

- No evidence of dementia - Mini Mental State Examination (MMSE) >=23 but some evidence
of cognitive impairment

- Must be aware of the nature of his current medical condition and must be willing to
give consent after being informed of the experimental nature of therapy,
alternatives, potential benefits, side-effects, risks and discomforts

- Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2 (Karnofsky score
>60%)

- Concurrent use of Coumadin or warfarin will be acceptable and monitoring patients on
warfarin or Coumadin will follow the standard of care as dictated by the prescribing
physician

- Must be willing to be monitored for adequacy of nutritional intake during the
intervention, as is the current standard of clinical practice. Menopausal status will
be obtained from all subjects. (Chemotherapy related amenorrhea will be defined as
without menstrual periods for a period equal to or over 6 months in a patient who was
premenopausal at diagnosis).

Exclusion Criteria:

- Use of estrogens (oral, dermal or vaginal), progesterone (oral or topical),
androgens, Raloxifene or Tamoxifen during the previous 3 months

- Use of over the counter steroid hormonal supplements including dehydroepiandrosterone
(DHEA)

- Patients with advanced or Stage IIIIB or IV breast cancer or other cancers

- Use of n-3 fatty acids or high dose antioxidant supplements other than what is
provided in the trial

- History of known allergy to components of the study supplements

- Renal or liver disease

- Mental illness judged by the Principal Investigator (PI) to preclude a successful
completion of the trial

- Concurrent participation in another chemoprevention trial

- Persons who are not native English speakers are excluded from the current proposal
because many of the cognitive tests that are administered are language-based and are
heavily influenced by first language.

- Evidence of bleeding diathesis or coagulopathy

- Other acute or chronic medical or psychiatric condition or laboratory abnormality
that may increase risk associated with study participation or study drug
administration, or may interfere with interpretation of study results, and in the
judgment of the investigator would make the subject inappropriate for entry into this
study